Tasimelteon is an oral compound in Phase III development for Non-24-Hour Disorder (Non-24), a circadian rhythm disorder with orphan designation in the U.S. and Europe. Tasimelteon is a circadian regulator that resets the master body clock in the suprachiasmatic nucleus (SCN) of the hypothalamus in the brain. Tasimelteon's ability to reset the master body clock in the SCN has been shown to synchronize the body's melatonin and cortisol circadian rhythms with the day-night cycle in patients with Non-24.
Non-24-hour Disorder (Non-24)is a chronic circadian rhythm disorder that occurs when individuals are unable to synchronize their endogenous circadian rhythm to the 24-hour day. Non-24 is most commonly found in blind individuals lacking the ability to perceive light, the primary environmental cue for synchronizing the circadian system daily. In general, individuals with Non-24 suffer from a variety of clinical symptoms as they cycle in-to and out-of phase resulting in disrupted nighttime sleep patterns and/or excessive daytime sleepiness.
For a complete list of clinical studies, go to ClinicalTrials.gov